Sangamo Therapeutics (SGMO) Net Margin (2016 - 2025)
Sangamo Therapeutics (SGMO) has 16 years of Net Margin data on record, last reported at 6012.05% in Q3 2025.
- For Q3 2025, Net Margin fell 603365.0% year-over-year to 6012.05%; the TTM value through Sep 2025 reached 342.22%, down 8436.0%, while the annual FY2024 figure was 169.45%, 2315.0% down from the prior year.
- Net Margin reached 6012.05% in Q3 2025 per SGMO's latest filing, down from 109.18% in the prior quarter.
- Across five years, Net Margin topped out at 21.6% in Q3 2024 and bottomed at 10205.61% in Q1 2024.
- Average Net Margin over 5 years is 2004.13%, with a median of 201.0% recorded in 2022.
- Peak YoY movement for Net Margin: plummeted -1021899bps in 2024, then skyrocketed 1003914bps in 2025.
- A 5-year view of Net Margin shows it stood at 166.96% in 2021, then decreased by -14bps to 190.76% in 2022, then plummeted by -1448bps to 2952.74% in 2023, then skyrocketed by 88bps to 359.94% in 2024, then plummeted by -1570bps to 6012.05% in 2025.
- Per Business Quant database, its latest 3 readings for Net Margin were 6012.05% in Q3 2025, 109.18% in Q2 2025, and 475.33% in Q1 2025.